No Data
Tianjin Pharmaceutical to Buy Controlling Stake in NewScen Coast Bio for $6 Million
07:36 AM EDT, 09/09/2022 (MT Newswires) -- Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) agreed to subscribe to up to 5.4 million shares in NewScen Coast Bio-Pharmaceutical at 8 yuan apiece for a
Tianjin Zhongxin Board OKs Use of $52 Million Placement Proceeds
08:07 AM EDT, 08/09/2022 (MT Newswires) -- The board of Tianjin Zhongxin Pharmaceutical Group (SGX:T14) approved the temporary use of 350 million yuan ($51.8 million) from the proceeds of a share plac
Tianjin Zhongxin Pharmaceutical Posts Lower Profit in January-March
03:51 AM EDT, 05/02/2022 (MT Newswires) -- Tianjin Zhongxin Pharmaceutical Group (SGX:T14) posted a lower net profit attributable to owners of the parent of 199.6 million yuan ($30.2 million) in the t
Tianjin Zhongxin Pharmaceutical Elects New Chairman; Shares Slip 3%
01:46 AM EST, 12/29/2021 (MT Newswires) -- The board of Tianjin Zhongxin Pharmaceutical Group (SGX:T14) has approved the appointment of Zhang Mingrui as its new chairman. Mingrui will remain chairman
The latest announcement of Lisheng Pharmaceutical: subsidiary cefdinir dispersible tablets pass consistency evaluation
According to Lisheng Pharmaceutical announcement, Tianjin Central Pharmaceutical Co., Ltd., a subsidiary of the company, received a "Drug Supplementary Application approval" (batch number: 2021B03871) and a "Drug Supplementary Application approval" (batch number: 2021B03872) of 0.1g cefdinir dispersible tablets (hereinafter referred to as "the drug") issued by the State Drug Administration. The two specifications of the drug (0.1g X 50mg) passed the generic drug quality and efficacy consistency evaluation. The third quarterly report of 2021 of Lisheng Pharmaceutical shows that the company's main revenue is 836 million yuan, down 8.71% from the same period last year, and the net profit of its mother is 9771.
The latest announcement of Lisheng Pharmaceutical: the net profit of 36.4642 million yuan in the third quarter increased by 61.33% over the same period last year.
Lisheng Pharmaceutical released a report for the third quarter of 2021, with operating income of 248 million yuan, down 17.66% from the same period last year. Net profit belonging to shareholders of listed companies was 36.4642 million yuan, up 61.33% from the same period last year. Net profit belonging to shareholders of listed companies after deducting non-recurring profits and losses was 35.7928 million yuan, up 57.46% from the same period last year; and basic earnings per share was 0.20 yuan. According to the 2021 report of Lisheng Pharmaceutical, the company's main income was 587 million yuan, down 4.32% from the same period last year; the net profit was 61.2528 million yuan, up 8.28% from the same period last year; and deducting non-net profit
SG Morning Bell: Stocks open higher on Monday; STI up 0.3%
Stocks to watch: a-iTrust, Sembmarine, Tianjin Zhong Xin, DBS, iFast, Nanofilm
Jinhushen Bio completes 67% acquisition with Tianjin Pharma, S shares offer price revised
